Basic information

Cardiothoracic Biopatch, a large group (more than 100,000 cases) has been used for long-term (15 years) repair and treatment of heart and macrovascular diseases in infants, young children, teenagers and adults of all ages. It is currently one of the few in China that can be used on the human body. Implantable products of animal origin for circulatory system implantation.

At present, the main treatment method for simple congenital heart disease is to repair and correct it with implant materials through congenital heart surgery. According to a report officially released by the Extracorporeal Circulation Branch of the Chinese Society of Biomedical Engineering, the number of congenital heart disease operations performed nationwide in 2017 was 77,305. Among them, 80% are surgeries for simple congenital heart diseases. Cardiac surgical biological patches are the main products used for surgical implantation in such patients. They have better biocompatibility than polyester patches and similar polymer materials.

The product is the first similar product approved for registration in China, filling a domestic gap.

Performance advantages

Surgical biopatch meets five levels of requirements for ideal soft tissue repair:

• Biocompatibility meets ISO10993
• Acts as an extracellular matrix scaffold for host cell growth
• Meets tissue's natural repair process
• Seamlessly integrates with host tissue to ensure complete repair in situ
• The reconstructed organization is indistinguishable from the original organization

Scope of application